Medicine Industry's Gateway to NICE

Trastuzumab deruxtecan is in clinical development for treatment of previously untreated advanced or metastatic non-small cell lung cancer (NSCLC), with HER2 genetic mutations. Lung cancer is the third most common cancer in the UK and NSCLC accounts for approximately 85% of all lung cancer cases, with around 1-4% of these being caused by mutations in […]

Bevacizumab gamma is in clinical development as an intravitreal injection (given through the white part of your eye known as vitreous) for the treatment of wet/neovascular age-related macular degeneration (nAMD). nAMD is a retinal condition that can cause deterioration of vision. nAMD can affect any part of your retina, a thin layer of tissue on […]

Diltiazem hydrochloride cream is in clinical development for the treatment of chronic anal fissure. An anal fissure is a small tear or cut in the lining of the skin around the back passage (anus). The most common symptoms of anal fissures include pain around the anus and bleeding when passing stools. Anal fissures often arise […]

Nifedipine-lidocaine has been clinically developed for the treatment of chronic anal fissure. An anal fissure is a tear or open sore (ulcer) that develops in the lining of the large intestine, near the anus. Many fissures heal by themselves, or certain medicines can be prescribed to treat them. However, sometimes a fissure does not heal […]

Pertuzumab biosimilar is in clinical development for the adjuvant and neoadjuvant treatment of invasive early stage or locally advanced breast cancer (BC) that is human epidermal growth factor 2 (HER2) positive (+). HER2 is a protein found on some cancer cells. Neoadjuvant therapy comes before primary treatment. Adjuvant therapy follows the primary treatment. BC is […]

Pirtobrutinib is in clinical development for the treatment of previously treated Bruton tyrosine kinase (BTK) inhibitor-naïve mantle cell lymphoma (MCL) in adults. MCL is a rare and aggressive blood cancer that starts in white blood cells (B cells) in the outer edge of the lymph nodes. The abnormal white blood cells start to collect in […]

Selumetinib granule formulation is currently in clinical development for the treatment of symptomatic and inoperable plexiform neurofibromas (PN) associated with type 1 neurofibromatosis (NF1) in children. NF1 is a genetic condition that causes tumours to grow along the nerves. The tumours are usually non-cancerous but may cause a range of symptoms. Some children have a […]

Savolitinib in combination with osimertinib is in clinical development for treatment of acquired mesenchymal epithelial transition factor (MET)-mediated osimertinib resistance in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). NSCLC is the most common form of lung cancers in the UK and at the metastatic stage, the disease has already spread from the […]

Soticlestat is in clinical development as an adjunctive therapy in patients with Dravet syndrome, a rare neurological condition characterized by treatment-resistant epilepsy, intellectual disability, and a spectrum of associated conditions such as behaviour, speech, feeding and mobility difficulties. Typically, Dravet syndrome involves multiple, frequent, and often prolonged seizures that do not respond well to treatment. […]

Lenvatinib in combination with pembrolizumab and chemotherapy is in clinical development as a first line therapy for metastatic squamous cell oesophageal carcinoma (SCOC). SCOC is a type of cancer that originates in the squamous cells that line the oesophagus (sometimes referred to as the food pipe or gullet). Metastatic cancer means the cancer has spread […]

Lenacapavir is in clinical development for the prevention of human immunodeficiency virus (HIV) in people who are at risk of HIV infection. HIV is a virus that damages the cells in the immune system and weakens the ability to fight everyday infections and disease. AIDS (acquired immune deficiency syndrome) is the name used to describe […]

Psoriatic arthritis is an inflammatory arthritis (a condition that causes pain and inflammation in a joint) associated with psoriasis. Psoriasis is a skin condition that causes flaky patches of skin which form scales. When this occurs in children it is referred to as juvenile psoriatic arthritis. Symptoms of juvenile psoriatic arthritis can include swelling of […]

Eosinophilic oesophagitis (EoE) is a chronic disorder of the digestive system in which large numbers of white blood cells called eosinophils are present in the tube that carries food from the mouth to the stomach (oesophagus). Eosinophils play a role in immune regulation. The production and accumulation of eosinophils seen in EoE may be caused […]

Eptinezumab is in clinical development for cluster headache. Cluster headaches are excruciating attacks of pain in one side of the head, often felt around the eye. The most common presentation the majority of patients with cluster headache have is the episodic form, in which attacks appear daily lasting for weeks or months, followed by a […]

Spesolimab is in development for the prevention of flares in generalised pustular psoriasis in adults and adolescents aged 12 years and over. Generalised pustular psoriasis is a rare dermatological condition characterised by the sudden appearance of multiple small blisters filled with pus (called pustules) on large areas of the skin on the body, arms, and […]

Lomitapide is currently in clinical development for the treatment of paediatric patients with homozygous familial hypercholesteraemia (HoFH) receiving stable lipid-lowering therapy. HoFH is a more severe form of familial hypercholesterolaemia, a condition passed down through families, which raises blood low density lipoprotein (LDL) cholesterol to very high levels. Low density lipoprotein cholesterol (LDL-C) is often […]

Retifanlimab is in clinical development as a combination therapy, with carboplatin and paclitaxel, for treating inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). SCAC is a rare cancer that starts in the squamous cells in the anal canal. Squamous cells make up the lining of the anal canal which is […]

Soticlestat is in clinical development as a secondary treatment used together with a primary treatment to enhance its effectiveness for patients with Lennox-Gastaut syndrome (LGS). LGS is a rare and severe form of childhood epilepsy characterized by tonic seizures (sudden stiffening of the body, often causing falls and injuries), atypical absence seizures (brief episodes of […]

Norucholic acid (NCA), (previously known as norursodeoxycholic acid (norUDCA) is in clinical development for treating primary sclerosing cholangitis (PSC). PSC is a rare and progressive chronic liver disease. In PSC the bile ducts (tubes which allow the liquid produced by the liver (bile) to flow from the liver to the small intestine where it helps […]

Targeted-release budesonide is in clinical development for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN). IgAN is one of the most common causes of chronic kidney disease and kidney failure and is caused by the immune system (the body's natural defences) producing a faulty version of an antibody, which is a protein, called IgA. […]

Mosunetuzumab is in clinical development for the treatment of relapsed or refractory follicular lymphoma (FL). FL is a type of blood cancer originating in the lymph nodes of the immune system, and it is the most common type of low-grade Non-Hodgkin’s Lymphoma in the UK. A relapsed or refractory cancer is one that has come […]

Resminostat is in clinical development for the maintenance treatment of adults with mycosis fungoides (MF) and Sézary syndrome (SS) which are the most common types of cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin lymphoma affecting the skin. CTCL can develop when T-cells become abnormal. T-cells are one of the important types of white […]

Somapacitan is in clinical development for the treatment of small for gestational age or Noonan syndrome or idiopathic short stature in patients aged 2 to 18 years. Idiopathic short stature is defined as shortness in childhood without a specific cause. This condition may be familial (run in families) or nonfamilial and may be associated with […]

Govorestat is in clinical development for treating classic galactosemia. Classic galactosemia is a rare disorder affecting the body’s ability to break down (metabolise) the sugar present in milk (galactose) into another type of sugar called glucose. Glucose provides a source of energy for body cells. Classic galactosemia is caused by a faulty (mutated) gene, meaning […]

Camlipixant is in clinical development for the treatment of adults with refractory or unexplained chronic cough. Cough is a normal reflex response to airway irritation, triggered by stimulation of airway cough receptors, which protect against choking and enhance airway clearance. Chronic cough is a persistent cough that lasts for eight weeks or longer. Refractory cough […]

Baloxavir marboxil is in clinical development for reducing direct transmission of influenza.Influenza commonly known as flu is an infection of the nose, throat, and lungs, which are a partof the respiratory system. There are three types of viruses that cause influenza; type A, B and C.Type A and B influenza viruses cause the main outbreaks […]

Bemarituzumab in combination with chemotherapy is in clinical development for the treatment of previously untreated locally advanced, or metastatic gastric or gastroesophageal junction (GEJ) cancer. Gastric (or stomach) cancer is when abnormal cells in the stomach start to grow and divide in an uncontrolled way. GEJ cancer starts in the junction where the food pipe […]